NYSE: PEN

Penumbra, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public.

If you purchased Penumbra securities, including options, between July 22, 2019 and December 15, 2020 and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Penumbra securities between July 22, 2019 and December 15, 2020 you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On November 9, 2020, market analyst Quintessential Capital Management released research report on the Company entitled “Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]”

Then on December 8, 2020, Quintessential Capital Management released a follow-up research report entitled “Is Penumbra’s core scientific research authored by a fake person?: The incredible story of Penumbra’s Dr. Antik Bose[.]” The follow-up report alleged that some of the Company’s scientific research pieces appear to have been incorrectly attributed or even authored by a fake individual. On this news, Penumbra’s share price fell $19.95 per share, or almost 9%, to close at $204.07 per share on December 8, 2020.

Finally, on December 15, 2020, after the markets closed, Penumbra announced that it was “voluntarily recalling all configurations” of its JET 7 Xtra Flex Reperfusion Catheter “because the catheter may become susceptible to distal tip damage during use. Distal tip damage in conjunction with pressurization or contrast injection may result in potential vessel damage, and subsequent patient injury or death.”

On this news, Penumbra’s shares fell $13.84 per share, or 7%, to close at $174.98 on December 16, 2020.

Follow us on:
Company Name: Penumbra, Inc.
Stock Symbol: PEN
Class Period: N/A
Court: N/A

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top